Literature DB >> 28653941

Transient thyrotoxicosis during nivolumab treatment.

M J van Kooten1, G van den Berg, A W J M Glaudemans, T J N Hiltermann, H J M Groen, A Rutgers, T P Links.   

Abstract

Two patients presented with transient thyrotoxicosis within 2-4 weeks after starting treatment with nivolumab. This thyrotoxicosis turned into hypothyroidism within 6-8 weeks. Temporary treatment with a beta blocker may be sufficient.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28653941

Source DB:  PubMed          Journal:  Neth J Med        ISSN： 0300-2977            Impact factor:   1.422


  3 in total

Review 1.  Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports.

Authors:  Meng H Tan; Ravi Iyengar; Kara Mizokami-Stout; Sarah Yentz; Mark P MacEachern; Li Yan Shen; Bruce Redman; Roma Gianchandani
Journal:  Clin Diabetes Endocrinol       Date:  2019-01-22

2.  Possible adverse effects of immunotherapy in non-small cell lung cancer; treatment and follow-up of three cases.

Authors:  Paul Zarogoulidis; Panos Chinelis; Anastasia Athanasiadou; Theodora Tsiouda; Georgia Trakada; Anastasios Kallianos; Lemonia Veletza; Dimitris Hatzibougias; Electra Mihalopoulou; Eirini Goupou; Christoforos Kosmidis; Chrysanthi Sardeli; Haidong Huang; Wolfgang Hohenforst-Schmidt
Journal:  Respir Med Case Rep       Date:  2017-07-14

3.  Nivolumab-induced autoimmune diabetes mellitus and hypothyroidism in a patient with rectal neuroendocrine tumor.

Authors:  Waqas Haque; Shabina R Ahmed; Mihail Zilbermint
Journal:  J Community Hosp Intern Med Perspect       Date:  2020-08-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.